Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
$MDNAF $MDNA
ir.medicenna.com/news-releases/…
English
RNA_Biotech
3.7K posts
RNA_Biotech
@RNA_Biotech
Stocks - Biotech - RNAi, mRNA, RNA tech, gene therapy, CRISPR - opinions, news, trading. Top Pick for 2026 $MDNAF $MDNA (.to)
Katılım Kasım 2013
127 Takip Edilen2.4K Takipçiler
@semodough yep, difficult for investors. You want to see them have cash, only problem, we can not see the reason nothing is happening. No interestest? Terms not good enough for CEO? possible deal for MDNA11 or MDNA55 soon? buyout? $MDNA $MDNAF
English
@RNA_Biotech Still looking for PIPE with somegood names - seeing nothing so far ???
English
Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
MDNA113 vs anti-PD-1 x IL-2α demonstrates superior tolerability, significantly wider therapeutic window
$MDNAF $MDNA
ir.medicenna.com/news-releases/…
English
RNA_Biotech retweetledi
$MDNAF $MDNA.TO $XBI They have the Map. They have the Machine. They have the Workarounds. What they don’t have is the one layer that decides whether any of it actually works.
Tomorrow: first real look at MDNA113 — the conditionally activated bispecific designed to execute without recreating the failure mode.
open.substack.com/pub/davidbakke…
English
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
$MDNA $MDNAF
ir.medicenna.com/news-releases/…
Medicenna Therapeutics@Medicenna1
We are pleased to welcome Dr. Nageatte Ibrahim as Chief Medical Officer (fractional) at Medicenna. With >20 years of oncology experience, her leadership will be pivotal as we advance our immunotherapy pipeline. $MDNAF $MDNA.TO
English
RNA_Biotech retweetledi
As we prep to share our latest #MDNA113 data at #AACR26, the #ImmunoOncology space is officially heating up!
There is a MASSIVE push in pharma for PD-1 bispecifics. We're seeing >$43 BILLION in recent combined transaction value in this space alone. $MDNAF $MDNA.TO
English
$mdna $mdnaf
Medicenna Therapeutics@Medicenna1
Unlocking immunologically "cold" tumors is one of oncology's greatest challenges. We are thrilled to announce that Medicenna will present highly anticipated preclinical data for our first-in-class IL-2-PD-1 Superkine, #MDNA113, at #AACR26 in San Diego! Read the full PR here: ir.medicenna.com/news-releases/… $MDNAF $MDNA.TO #Biotech #Oncology #Immunotherapy #CancerResearch (Disclaimer: MDNA113 is investigational. Post contains forward-looking statements. See SEDAR/SEC filings for risks).
QCT
RNA_Biotech retweetledi
$MDNAF $MDNA.to to present MDNA-113 at #AACR26 04/21/2026
Notably, immunodynamic and safety data from non-human primate studies will highlight the differentiated profile of MDNA113
ir.medicenna.com/news-releases/…
dough@semodough
$MDNAF Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026 - Medicenna Therapeutics ir.medicenna.com/news-releases/…
English
$MDNAF is showing serious strength. 📈
• Up 27% from recent lows
• Reclaimed the 20-Day MA✅
• Cleared the 50-Day MA ✅
• Eyes on the 200-Day MA next 🎯
$MDNA $XBI #Biotech #StockMarket
English
$MDNA $MDNAF
7th Annual Glioblastoma Summit: February 19
BIO Investment and Growth Summit : March 2-3
38th Annual ROTH Conference: March 22-24
BIO-Europe Spring Conference: March 23-25
Medicenna Therapeutics@Medicenna1
$MDNAF $MDNA.TO Medicenna is hitting the road! Today we announced our Spring 2026 conference lineup. Kicking off TOMORROW in Boston: CEO Dr. Fahar Merchant presents clinical updates on bizaxofusp in recurrent #Glioblastoma at the 7th Annual GBM Summit. 🔗 PR:ir.medicenna.com/news-releases/… 🧵 1/2
English
Medicenna Third Quarter Fiscal 2026
ABILITY-1 new expansion cohort NSCLC and colorectal cancer (mono- and combination in TMB-H and MSI-H cohorts) (both have blockbuster market opportunities)
$MDNA $MDNAF
ir.medicenna.com/news-releases/…
English
$MDNAF $MDNA
great work by David: PRISM-11 external scientific-intelligence and interpretive framework now used by the company
substack.com/home/post/p-18…
English
Participants: 80 participants
Sites: 8 sites in 1 country
This is probably a $15M+ trial that Fondazione Melanoma Onlus will be funding.
$MDNAF $MDNA
English
Overall trial status:
" Authorised, recruitment pending"
Lots of work has already been done. Trial is further along than most would think.
$MDNAF $MDNA
English
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11....
$MDNA $MDNAF
ctis.eu/search/trial/2…
English
$MDNAF $MDNA
update after ESMO data
MDNA113 update january
MDNA11 enrollment complete end Q1 2026
15 patients/tumor type
Meet regulators Q2 - MDNA11
Martin Gagel@RadiusResearch
🧬 MDNA11 Clinical Trial Results Update @Medicenna1 (TSX: $MDNA | OTCQX: $MDNAF) CEO Fahar Merchant reviews newly presented clinical data from the ongoing Phase 1/2 ABILITY-1 study evaluating #MDNA11 in patients with advanced solid tumours. ▶️ Watch the full update here >> youtu.be/PpUdquhGbV0 #Biotech #Immunotherapy #ClinicalTrials #Oncology #DrugDevelopment #Biopharma
Filipino
Werewolf Therapeutics Announces Pipeline and Business Updates
- 43%
$howl
finance.yahoo.com/news/werewolf-…
English
Today’s $60M valuation only makes sense if MDNA11 fails
Data do not justify that assumption anymore
Even with dilution, risk-adjusted value is multiples higher
Pharma does not need huge N to justify engagement they need durability+biology, which MDNA11 is showing
$MDNAF $MDNA
English
